BMO Capital Markets Reiterates Underperform Rating, $30 PT on Zoetis on Avian Flu Scare
In a report published Friday, BMO Capital Markets analyst Alex Arfaei reiterated an Underperform rating and $30.00 price target on Zoetis (NYSE: ZTS).
In the report, Arfaei noted, “Shares of Zoetis are weak today in part related to the 14 human cases of the H7N9 virus, an unusual strain of bird flu that has so far killed six people in China, which has in turn led the Chinese authorities to kill more than 20,000 birds from a live-poultry trading zone. Shanghai will temporarily close all its live poultry markets starting Saturday.”
Zoetis closed on Thursday at $31.84.
Latest Ratings for ZTS
|Sep 2016||Bank of America||Initiates Coverage on||Buy|
|Sep 2016||Argus Research||Maintains||Below Average|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.